SEC 13F Intelligence

Managers / Q4 2019 · view latest →

SV Health Investors, LLC

CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100

Reported Value
$165M
Q4 2019
Positions
10
Filings on Record
16
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Sv Health Investors, LLC reported $165M in U.S.-listed holdings across 10 positions for Q4 2019.

Its largest position, Misonix, represents 19.1% of the portfolio.

The book was largely unchanged from Q3 2019.

Portfolio Metrics

Turnover
+6.7%
vs prior filed quarter
Top-10 Concentration
+100.0%
share of reported value
Largest Position
+19.1%
Misonix

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $162MQ4 ’18Q1 ’19: $170MQ2 ’19: $149MQ2 ’19Q3 ’19: $142MQ4 ’19: $165MQ4 ’19Q1 ’20: $119MQ2 ’20: $144MQ2 ’20Q3 ’20: $197MQ4 ’20: $208MQ4 ’20Q1 ’21: $267MQ2 ’21: $230MQ2 ’21Q3 ’21: $204MQ4 ’21: $155MQ4 ’21Q1 ’22: $83MQ2 ’22: $44MQ2 ’22Q3 ’22: $32Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 59.6%Other: 29.4%ADR: 10.9%
  • Common Stock · 59.6% · $98M
  • Other · 29.4% · $49M
  • ADR · 10.9% · $18M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TRANSENTERIX INCTRIMMED−6.12M510.1K−$3M$750,000
DECIPHERA PHARMACEUTICALS INCTRIMMED−92.2K450.0K+$10M$28M
KALVISTA PHARMACEUTICALS INCHELD+01.72M+$11M$31M
AVROBIO INCHELD+01.42M+$9M$29M
BCYCBICYCLE THERAPEUTICS PLCHELD+01.92M−$4M$18M
SUTRO BIOPHARMA INCHELD+01.82M+$3M$20M
MISONIX, INC.HELD+01.70M−$3M$32M
X4 PHARMACEUTICALS INCHELD+0311.5K−$624,000$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

10 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MISONIX, INC.COM19.12%$32M1.70M
2KALVISTA PHARMACEUTICALS INCCOM18.55%$31M1.72M
3AVROBIO INCCOM17.28%$29M1.42M
4DECIPHERA PHARMACEUTICALS INCCOM16.96%$28M450.0K
5SUTRO BIOPHARMA INCCOM12.16%$20M1.82M
6BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS10.94%$18M1.92M
7X4 PHARMACEUTICALS INCCOM2.02%$3M311.5K
8OCULOCULAR THERAPEUTIX INChistory →COM1.50%$2M628.2K
9CATABASIS PHARMACEUTICALS INCOM NEW1.02%$2M285.8K
10TRANSENTERIX INCCOM NEW0.45%$750,000510.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$32M4Nov 7, 202213F-HRchanges · EDGAR ↗
Q2 2022$44M5Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$83M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M6Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$204M8Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$230M7Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$267M8May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$208M9Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$197M10Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$144M10Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$119M10May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M10Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M10Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$149M9Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$170M8May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$162M9Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 2 additional managers.

  • SVLSF VI, LLC028-19256
  • SV Life Sciences Fund VI (GP), L.P.028-19255

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.